Genentech’s Herceptin® (trastuzumab) has received additional U.S. Food and Drug Administration approval for two new Herceptin-containing regimens for the adjuvant treatment of early HER2-positive breast cancer.
Based on results from the phase III BCIRG 006 trial, both the TCH (Taxotere® and carboplatin with Herceptin) as well as the AC-TH (doxorubicin and cyclophosphamide followed by Taxotere with Herceptin) were approved as adjuvant therapy for HER2-positive breast cancer.
The TCH regimen does not contain an anthracycline and has been associated with low cardiotoxicity.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
